Digest Network Come funziona
Network
/
Società
Or
Non verificato

OrsoBio, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

6 comunicati stampa

Guarda tutti i comunicati
16/01/2026
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Industria
OrsoBio Announces Nature Medicine Publication Establishing Clinical and Mechanistic Validation of First-in-Class LXR Inverse Agonist TLC-2716 for the Treatment of Serious Metabolic Diseases
Fonte
OrsoBio, Inc.
Emittente
Business Wire
1.00
0
16/12/2025
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
OrsoBio Announces Positive Topline Phase 1b/2a Clinical Data for its Oral Mitochondrial Protonophore TLC-6740 in Combination with Tirzepatide
Fonte
OrsoBio, Inc.
Emittente
Business Wire
1.00
0
04/11/2025
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Eventi
Industria
OrsoBio to Present Clinical and Preclinical Data on Mitochondrial Protonophore Portfolio for Obesity at ObesityWeek® 2025
Fonte
OrsoBio, Inc.
Emittente
Business Wire
1.00
0
20/06/2025
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Eventi
Industria
OrsoBio to Present Preclinical Data on Mitochondrial Protonophore Portfolio in Models of Obesity at the American Diabetes Association’s 85th Scientific Sessions
Fonte
OrsoBio, Inc.
Emittente
Business Wire
1.00
0
15/10/2024
Industria
Salute
Medicina - Varie
Farmaceutica
Cardiologia
Biotecnologia
OrsoBio Announces Publication of Preclinical Data on Novel Approach for Regulating Metabolic Dysfunction and Reducing Inflammation and Fibrosis
Fonte
OrsoBio, Inc.
Emittente
Business Wire
1.00
0
06/09/2024
Mercato del lavoro
Industria
Scienza
Cardiologia
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
OrsoBio Announces Oversubscribed $67 Million Series B Financing to Accelerate Mitochondrial Protonophore Portfolio Targeting Obesity and Associated Disorders
Fonte
OrsoBio, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0